Company intelligence / Profile preview

HighLife

Ownership: Private
Development stage: Other

Overview

The proprietary transcatheter mitral valve replacement technology has shown convincing data and is being evaluated in pivotal regulatory approval trials for CE mark and first-in-human studies. The device is designed to be implanted via a minimally invasive procedure on a beating heart, preserving native anatomy and reducing trauma compared to open-heart surgery. Clinical results are promising but not yet commercialized.

Therapeutic areas: Cardiovascular
Modalities: Device
Industry: Implantable Medical Devices

Partnerships

Peijia Medical holds a license agreement for China

Beyond the preview

Go deeper on HighLife.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HighLife.

Explore the full profile